Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Oct 26 - Oct 31
185 To circumvent resistance and expand the scope of DDR targeting, next-generation agents such as ATR, CHK1, WEE1, and DNA-PK inhibitors are being investigated, both as monotherapies and in combination with DNA-damaging agents
(2022) Dose-response relationship between weight loss and improvements in obstructive sleep apnea severity after a diet/lifestyle interventions: secondary analyses of the MIMOSA randomized clinical trial Olukorode, John O., et al (2024) Recent Advances and Therapeutic Benefits of Glucagon-Like Peptide-1 (GLP-1) Agonists in the Management of Type 2 Diabetes and Associated Metabolic Disorders Olukorode, John O., et al (2024) Recent Advances and Therapeutic Benefits of Glucagon-Like Peptide-1 (GLP-1) Agonists in the Management of Type 2 Diabetes and Associated Metabolic Disorders Olukorode, John O., et al (2024) Recent Advances and Therapeutic Benefits of Glucagon-Like Peptide-1 (GLP-1) Agonists in the Management of Type 2 Diabetes and Associated Metabolic Disorders Gonzolaz-Rellan, Maria J., Drucker, Daniel J
G.GratadouxJ
If you travel regularly, prepare a travel kit with all necessary supplies
Wu, Y., et al
